Akebia Therapeutics, Inc. Gains 33.73%
Fri, Mar 14, 2025 at 07:44 PM
Akebia Therapeutics, Inc. (AKBA:NASDAQ) shot up at $2.26, representing a gain of 33.7%. On Fri, Mar 14, 2025, AKBA:NASDAQ touched a New 2-Week High of $2.26. The stock got featured on our News Catalysts scanner on Thu, Mar 13, 2025 at 10:07 AM in the 'EARNINGS' category. From Fri, Feb 28, 2025, the stock recorded 40.00% Up Days and 54.55% Green Days
The stock spiked on Thu, Jan 23, 2025 at $2.41 with a volume of 2M+.
About Akebia Therapeutics, Inc. (AKBA:NASDAQ)
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
Top 10 Gainers:
- LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 195.08%
- Bon Natural Life Limited (BON:NASDAQ), 95.73%
- SUNation Energy Inc Com Par $0.05 (SUNE:NASDAQ), 64.11%
- D-Wave Quantum Inc. (QBTS:NYSE), 46.89%
- Applied Optoelectronics, Inc. (AAOI:NASDAQ), 39.32%
- Purple Innovation, Inc. (PRPL:NASDAQ), 35.63%
- Akebia Therapeutics, Inc. (AKBA:NASDAQ), 33.73%
- VCI Global Limited (VCIG:NASDAQ), 30.31%
- Hauchen AI Parking Management Technology Holding Co. Ltd. (HCAI:NASDAQ), 30.23%
- Banzai International, Inc. Class A Common Stock (BNZI:NASDAQ), 29.78%